GSM gold starGSM Global
中文版 · Chinese

STEP Young Phase 3 Trial in The New England Journal of Medicine, Announced November 16: BMI Fell 17.4% at Week 68 in 167 Children Aged 6 to Under 12, Versus a 2.2% Rise on Placebo

Monday, November 16, 2026 · Health · GSM News

Novo Nordisk announced the primary results of the Phase 3 STEP Young trial on November 16; the results were presented at a scientific symposium at ObesityWeek 2026 and simultaneously published in The New England Journal of Medicine. The trial evaluated once-weekly semaglutide injection, combined with a reduced-calorie diet and increased physical activity, in children aged 6 to under 12 years with obesity.

STEP Young was a randomized, double-blind, placebo-controlled multinational trial enrolling 167 children, 112 on semaglutide and 55 on placebo, with a maximum dose of 1.7 mg or 2.4 mg set by baseline body weight. More than 85% of the children had class II or III severe obesity at baseline.

At week 68, on the efficacy estimand, the estimated mean percentage change in BMI was −17.4% with semaglutide and +2.2% with placebo, an estimated treatment difference of −19.7 percentage points. A BMI reduction of 10% or more was observed in 78.7% of semaglutide-treated children versus 0% on placebo; 83.0% of the semaglutide group improved their BMI category, versus 23.5% on placebo; and 40.4% of semaglutide-treated children were no longer classified as having obesity, versus 0% on placebo.

The company said the safety and tolerability profile was consistent with previous pediatric and adult semaglutide trials, with no unexpected safety concerns and no safety concerns identified for growth or pubertal development. Semaglutide injection is not approved in the United States for children under 12, and its safety and efficacy in that population are not established.

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:Semaglutide PDB=7ki0.png — Deposition authors: Zhang, X., Belousoff, M.J., Danev, R., Sexton, P.M., Wootten, D. et al. Licensing: CC0.

Latest in Health